You can buy or sell CBIO and other stocks, options, ETFs, and crypto commission-free!
Catalyst Biosciences, Inc. Common Stock, also called Catalyst Biosciences, is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address serious medical conditions. Read More Its pipeline includes hemostasis such as Factor VIIa marzeptacog alfa, Factor IX dalcinonacog alfa, and Factor Xa; and anti-complement. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Simply Wall StFeb 28
Could Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Investor Composition Influence The Stock Price?
If you want to know who really controls Catalyst Biosciences, Inc. (NASDAQ:CBIO), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership. Catalyst Biosciences is a smaller company with a market capitalization of US$104m, so it may still be flying under the radar of many institutional inve...
Expected May 2, Pre-Market